STING1 and neoplasm: Recently, the pivotal role of STING in sustaining innate immune responses in the tumour microenvironment has been validated [14]; and structure–function studies of mouse STING (mSTING) and human STING (hSTING) suggested that DMXAA is a potent agonist of mSTING, while polymorphism in hSTING makes it unable to bind the compound, and this probably explains its failure in clinical trials [15].